MAVS-WT Citations (3)

Originally described in: Peroxisomes are signaling platforms for antiviral innate immunity.
Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C, Shum B, Hacohen N, Chen ZJ, Whelan SP, Fransen M, Nibert ML, Superti-Furga G, Kagan JC Cell. 2010 May 14;141(4):668-81. Epub 2010 May 6. PubMed Journal

---

Articles Citing MAVS-WT

Articles
Replication defective viral genomes exploit a cellular pro-survival mechanism to establish paramyxovirus persistence. Xu J, Sun Y, Li Y, Ruthel G, Weiss SR, Raj A, Beiting D, Lopez CB. Nat Commun. 2017 Oct 6;8(1):799. doi: 10.1038/s41467-017-00909-6. PubMed
Viperin interacts with PEX19 to mediate peroxisomal augmentation of the innate antiviral response. Khantisitthiporn O, Shue B, Eyre NS, Nash CW, Turnbull L, Whitchurch CB, Van der Hoek KH, Helbig KJ, Beard MR. Life Sci Alliance. 2021 Jun 9;4(7). pii: 4/7/e202000915. doi: 10.26508/lsa.202000915. Print 2021 Jul. PubMed
Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease. Xu Y, Chen K, Pan J, Lei Y, Zhang D, Fang L, Tang J, Chen X, Ma Y, Zheng Y, Zhang B, Zhou Y, Zhan J, Xu W. Int J Biol Macromol. 2021 Oct 1;188:137-146. doi: 10.1016/j.ijbiomac.2021.07.184. Epub 2021 Aug 6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.